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The combinatorial action of separate cisacting elements controls the cell-specific expression of type I collagen genes. In particular, we have shown that two short elements located between -3.2 and -2.3 kb and named TSE1 and TSE2 are needed for expression of the mouse COL1a1 gene in tendon fibroblasts. In this paper, we analyzed the trans-acting factors binding to TSE1 and TSE2. Gel shift experiments showed that scleraxis (SCX), which is a basic helix-loophelix transcription factor that is expressed selectively in tendon fibroblasts, binds TSE2, preferentially as a SCX/E47 heterodimer. In transfection experiments, overexpression of SCX and E47 strongly enhanced the activity of reporter constructs harboring either four copies of TSE2 cloned upstream of the Type I collagen is the most abundant extracellular matrix protein in vertebrates. It is composed of two α1 chains and one α2 chain that are coiled around each other in an uninterrupted triple helix. In the extracellular space, type I collagen molecules selfassemble into highly organized fibrils and then into fibers. The high tensile strength of these fibers is essential to provide mechanical strength to tissues, and in particular to bone, tendon and ligament. This is exemplified by the dramatic consequences of genetic diseases resulting from mutations in one of the genes encoding type I collagen, such as osteogenesis imperfecta or Ehlers-Danlos syndromes type VIIA and VIIB (1) . The hallmark of osteogenesis imperfecta is brittle bones, but the disease can also involve other tissues rich in type I collagen, such as ligaments, tendons, fascia, sclerae, and teeth. Ehlers-Danlos syndromes are characterized by skin hyperextensibility, vascular fragility, and increased ligament elasticity responsible for joint hypermobility. Although type I collagen is widely distributed throughout the body, it is produced by a discrete subset of cells, including fibroblasts, osteoblasts and odontoblasts. Studies performed using transgenic mice harboring various segments of the mouse, rat, or human type I collagen promoters cloned upstream of a reporter gene have shown that the cell-specific expression of type I collagen genes is based on a modular organization of separate cell-specific cis-acting elements (2) (3) (4) (5) . In particular, the segment of the mouse pro-α1(I) collagen (COL1a1) promoter located downstream of -2.3 kb induces highlevel expression of reporter genes in osteoblasts of transgenic mice, while the segment of COL1a1 located between -3.2 and -2.3 kb drives high-level expression of the lacZ reporter gene specifically in tendon, ligament and fascia fibroblasts (4, (6) (7) (8) . Analysis of this latter segment has shown that two short cis-acting elements, named TSE1 and TSE2, are necessary for activation of the COL1a1 promoter in tendon fibroblasts (8) . TSE2 is located between -2,363 and -2,316 bp. It contains a consensus E-box (CACGTG) that is located at -2,325 bp, and binds a tendon-specific nuclear protein (8) . TSE1 is located between -2,845 and -2,741 bp, and its 3' half is necessary for expression of the lacZ reporter gene in tendons of transgenic mice (8) .
Molecular mechanisms responsible for the differentiation of mesenchymal cells into tendon fibroblasts are still largely unknown (9) . Few DNA-binding proteins have a pattern of expression restricted to developing tendons, which suggests that they could regulate tendon cell fate. The Eya1, Eya2 and Six2 genes are expressed in limb tendons, with Eya1 and Six2 being largely restricted to the flexor tendons and Eya2 to the extensor tendons (10, 11) . Scleraxis (SCX), which is a member of the basic helixloop-helix (bHLH) family of transcription factors, is specifically expressed in tendons and ligaments, where it can be detected from early progenitor cells to mature fibroblasts (12) (13) (14) . As most bHLH transcription factors that have a restricted pattern of expression, SCX heterodimerizes with the E2A gene products and binds E-boxes as SCX/E12 or SCX/E47 heterodimers (12, 15, 16) . Recently, it has been shown that overexpression of SCX in tendon fibroblasts upregulates the expression of the tenomodulin gene (17) . This latter gene encodes a transmembrane protein that is expressed selectively in tendons, ligaments, and epimysium of skeletal muscle, and can be considered as a phenotypic marker of tendon fibroblasts (18) . However, tenomodulin may not be a direct target of SCX. It has also been shown that a biologically active variant of Smad8 promotes the differentiation of C3H10T1/2 mesenchymal cells into tendon fibroblasts in the presence of bone morphogenetic protein 2, indicating that this Smad pathway is involved in the differentiation of mesenchymal cells into tendon fibroblasts (19) . In particular, it induced the expression of the SCX, EphA4 and COL1a1 genes. However, the genes that are direct targets of Smad8 have not been identified.
The NFATc family of transcription factors is composed of five members, NFATc1/NFAT2/NFATc, NFATc2/NFAT1/NFATp, NFATc3/NFAT/NFATx, NFATc4/NFAT3 and the atypical member NFAT5. There is a tight regulation of the subcellular localization of these proteins, through the action of calcineurin, a calmodulindependent serine/threonine phosphatase. Under basal conditions, NFATc proteins are localized in the cytoplasm in a hyperphosphorylated latent form. Sustained increase in intracellular calcium concentration leads to calcineurin activation, and subsequently NFATc dephosphorylation and translocation into the nucleus where they bind to cisacting elements (20) . Although originally described in immune cells, members of the NFATc family are expressed in many cell types outside of the immune system and are involved in processes such as heart valve development, chondrogenesis, skeletal muscle growth and angiogenesis (21, 22) .
In this paper, we demonstrate that SCX binds TSE2, preferentially as a SCX/E47 heterodimer, and activates the COL1a1 proximal promoter in transient transfection experiments. We also show that DNA-binding proteins of the NFATc family are present in tendon fibroblasts, bind TSE1, and transactivate the COL1a1 proximal promoter in transient transfection experiments. Conversely, inhibition of the nuclear translocation of these proteins strongly decreases the expression of COL1a1 in tendon fibroblastic cells. Taken together, these data suggest that SCX and NFATc activate the COL1a1 gene in tendon fibroblasts, and are part of a regulatory network involved in differentiation of mesenchymal cells into tendon fibroblasts.
MATERIAL AND METHODS

DNA constructs
For transfection experiments, various segments of the COL1a1 proximal promoter were cloned upstream of the lacZ gene in the placH reporter plasmid (4). pJ320 contains a segment of the COL1a1 promoter extending from -3,150 to +110 bp. p4TSE1mp contains four copies of TSE1 (i.e. the COL1a1 promoter sequence extending from -2,790 to -2,741 bp) cloned upstream of the COL1a1 minimal promoter that extends from -220 to +110 bp. p4TSE2mp contains four copies of TSE2 (i.e. the sequence of the COL1a1 promoter extending from -2,363 to -2,316 bp) cloned upstream of the COL1a1 minimal promoter. pJ320-MTSE2 is identical to pJ320, except that the E box in TSE2 was mutated (CACGTG → GGATCC) by sitedirected mutagenesis using the QuickChange Site-directed Mutagenesis Kit (Stratagene) and following the manufacturer's instructions.
The mouse cDNA encoding SCX (a gift from E. Olson, Southwestern University, Dallas, TX) was cloned in the pcDNA3.1 expression vector (Invitrogen), which contains an Xpress tag upstream of the multiple cloning site, to generate pcDNA-SCX. The mouse cDNAs encoding E12 and E47 (a gift from C. Murre, University of California at San Diego, La Jolla, CA) were cloned into the pCI expression vector (Promega), generating pCI-E12 and pCI-E47, respectively. The expression vectors pREPNFATc1, pREP-NFATc3 and pREP-NFATc4 were given by C. Wilson (University of Washington, Seattle, WA).
pGL3 control vector (Promega), containing the SV40 promoter/enhancer cloned upstream of the luciferase reporter gene, was used as efficiency control for transfection experiments.
Cell cultures
NIH/3T3 fibroblasts and COS-7 cells were obtained from ATCC-LGC Promochem and cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum, at 37°C in a 5% CO 2 atmosphere. C2 myoblastic cells, a gift of H. Alameddine (INSERM U582, Paris), were grown in DMEM supplemented with glutamax-I, 4.5 g/L glucose and 20% fetal bovine serum, at 37°C in a 5% CO 2 atmosphere. TT-D6 tendon fibroblasts were cultured in alpha MEM supplemented with 1% penicillin/streptomycin and 0.5% fetal bovine serum, at 33°C in a 5% CO 2 atmosphere (23).
Gel shift assays
For gel shift assays, we used nuclear extracts from TT-D6 cells or from COS-7 cells transfected with pcDNA, pCI, pcDNA-SCX, pCI-E47 or pcDNA-SCX and pCI-E47. The nuclear extracts were prepared as previously described, but were not dialyzed (24) . The probes were end-labeled by filling-in with [α-32 P]dCTP using the Klenow fragment of the E coli DNA polymerase I (Invitrogen). The following double-stranded synthetic oligonucleotides were used as probes or competitors:
To study the binding of SCX to TSE2, the TSE2 probe was incubated with 5 µg of nuclear extracts from transfected COS-7 cells for 30 min at room temperature in a reaction mixture containing 50 mM Tris-HCl, 50 mM NaCl, 10 µM ZnSO 4 , 1 mM DTT, in the presence of 1 µg of poly(dIdC).poly(dI-dC) (Sigma). The complexes were fractionated on 4% polyacrylamide gels in 1X TBE. Since SCX binds the AgE sequence of the aggrecan promoter, we used it as a competitor (25) . For competition experiments, a 200-fold molar excess of unlabeled double-stranded oligonucleotides were added to the reaction mixture. In some cases, nuclear extracts from COS-7 cells transfected with pcDNA-SCX and pCI-E47 were preincubated with 2 µg of anti-Xpress antibody (Invitrogen) for 30 min at room temperature, before addition of labeled probe.
To analyze the binding of NFATc proteins to TSE1, the TSE1 probe was incubated with 5 µg of nuclear extracts from TT-D6 cells, for 30 min at room temperature in a reaction mixture containing 50 mM KCl, 25 mM HEPES, 0.05 mM EDTA, 5% glycerol, 1 mM DTT, 100 ng bovine serum albumin and in the presence of 1 µg of poly(dI-dC).poly(dI.dC) (Sigma). Since NFATc proteins bind the IL-4wt sequence (26), we used it as a competitor. The same sequence but with a mutated GGAAA motif (IL-4mut) was used as control. For competition experiments, different amounts of unlabeled double-stranded oligonucleotides were added to the reaction mixture. The DNA-protein complexes were resolved by electrophoresis on 6% polyacrylamide gels in 1X TBE.
Transfection experiments
Transfections were carried out using Lipofectamine PLUS reagent (Invitrogen) and following the manufacturer's instructions.
For stable transfection experiments, NIH/3T3 fibroblasts were cotransfected in triplicate with linearized pJ320 plasmid and linearized plasmid expressing the neomycin resistance gene (pSVneo, Promega). Starting 48 hours later, pools of resistant clones (NIH/3T3-pJ320 clones) were selected by treatment with G418 (Life Technologies).
For transient transfection experiments, cells were cotransfected with various amounts of expression vectors, 100 ng of pGL3 control vector, and 900 ng of a lacZ reporter construct, except for the NIH/3T3-pJ320 cells that already harbored a reporter construct. Forty eight hours after transfection, cells were lysed in 0.1 M potassium phosphate buffer, pH 7.8, 1 mM DTT and the β-galactosidase and luciferase activities were assessed using the β-Gal reporter gene assay (Roche) and the luciferase assay system (Promega), respectively. For cells transiently transfected with a lacZ reporter construct, β-galactosidase activities were normalized to luciferase activities, to compensate for variations in transfection efficiency. For the stably transfected NIH/3T3-pJ320 cells, β-galactosidase activities were normalized to the amount of protein. All transient transfection experiments were done in triplicate and repeated at least three times.
RT-PCR assays
To prepare total RNA, cells were lysed in trizol (Invitrogen), while tissue samples were homogenized in the presence of trizol. Total RNA was then isolated following the manufacturer's instructions and treated with DNase I (Invitrogen). It was reverse transcribed using random primers (Invitrogen) and SuperScript II reverse transcriptase (Invitrogen). As a control, a reverse transcription (RT) reaction was always performed after omitting the reverse transcriptase. All RT reactions were tested for DNA contamination.
PCR reactions specific for each NFATc were carried out for 30 cycles, using the primers which are listed in Table 1 . To monitor the efficiency of the RT-PCR reactions, PCR with primers corresponding to the constitutively expressed β-actin gene (Table 1) were systematically performed.
For real-time RT-PCR experiments, PCR assays were performed in a LightCycler system (Roche Diagnostics), using the LightCycler FastStart DNA Master SYBR Green I kit, 0.3 µM of β-actin primers and 0.4 µM of COL1a1 or COL1a2 primers (Table1). Amplification of β-actin was used for normalization. Normalized data are expressed as a percentage of COL1a1 or COL1a2 mRNA expression in untreated cells.
In some experiments, 70-80 % confluent TT-D6 or NIH/3T3 cells were treated with different amounts of either cyclosporine A (CsA, Sandimmun ® , Novartis) or INCA-6 (27) before harvesting RNA. When INCA-6 was used, the medium containing INCA-6 was replaced by fresh cell-culture medium after 1 h. Total RNA was extracted after 72 h when cells were treated with CsA or after 48 h when they were treated with INCA-6, and used for real-time RT-PCR assays. All experiments were done in triplicate and repeated at least three times.
Western blot experiments
For Western blot analyses, we used nuclear extracts from TT-D6 cells and NIH/3T3 fibroblasts, that were prepared as described above, and total cell lysates from COS-7 cells transfected with an expression vector encoding NFATc1, NFATc3 or NFATc4, as positive controls. Briefly, COS-7 cells were transfected with pREP-NFATc1, pREP-NFATc3 or pREP-NFATc4 as described above. After 48 h, the cells were washed with cold PBS and lysed in buffer containing 50 mM Tris.Cl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS, supplemented with protease inhibitors. Then, 25 µg of nuclear proteins or 10 µg of cell lysates were fractionated on a 7.5% SDSpolyacrylamide gel, electrotransferred onto a nitrocellulose membrane (Hybond TM -ECL TM , Amersham Biosciences), incubated with a monoclonal antibody directed against the mouse NFATc1 (sc-7294, Santa Cruz), NFATc3 (sc-8405, Santa Cruz) or NFATc4 (sc-13036, Santa Cruz) protein and then with a peroxidase-labeled secondary antibody. Specific immune complexes were visualized by chemiluminescence using the Western lightning chemiluminescence reagent plus (Perkin Elmer).
In situ hybridization experiments
E 15.5 mouse embryos were fixed in 4% paraformaldehyde, and processed for in situ hybridization to wax sections as previously described (28, 29) . The SCX probe was used as previously described (29) . The probes for NFATc1, NFATc3, NFATc4 originate from the UNIGENE database. Probes were transcribed in the presence of digoxigenin coupled to uridine. The digoxigenin-labeled probes were revealed by immunohistochemistry using nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indodyl phosphate (28) .
Differentiated muscle cells were detected after in situ hybridization using the MF20 monoclonal antibody against sarcomeric myosin heavy chain (Developmental Hybridoma Bank), a horseradish peroxidase-conjugated secondary antibody and diaminobenzidine as substrate (28) .
Statistical analyses
Results are presented as mean ± SD. Statistical analyses were performed by one-way ANOVA followed by post-hoc tests, or by unpaired Student's t-test, as appropriate using Statview 5.0 software (SAS, Cary, NC). p values < 0.05 were considered as significant.
RESULTS
TSE2 contains an E box that binds the heterodimer scleraxis/E47
Gel shift assays have shown that TSE2 binds a tendon-specific nuclear protein, and that the binding site for this protein encompasses a consensus E-box (CACGTG) located at -2,325 bp (8) . Since Eboxes are known to bind bHLH transcription factors, we speculated that TSE2 might bind SCX. To test this hypothesis, we performed gel shift assays using an end-labeled TSE2 probe. Since SCX can bind DNA as an homodimer or as a SCX/E12 or SCX/E47 heterodimer (12, 15) , this probe was incubated with reticulocyte lysates containing SCX alone, SCX and E12, or SCX and E47. A retarded band was observed when TSE2 was incubated with reticulocyte lysates containing SCX plus E47 but not when it was incubated with reticulocyte lysates containing SCX plus E12 or containing only SCX, E47 or E12 (data not shown). Similar results were obtained when gel shift assays were repeated using TSE2 and nuclear extracts from COS-7 cells transfected with pcDNA, pCI, pcDNA-SCX, pCI-E47, or pcDNA-SCX plus pCI-E47 (Fig. 1A) . Incubation of TSE2 with nuclear extracts from COS-7 cells transfected with pcDNA-SCX plus pCI-E47 (lane 5) induced the formation of a complex that was not observed with nuclear extracts from COS-7 cells transfected with pcDNA (lane 1), pCI (lane 2), pcDNA-SCX (lane 3) or pCI-E47 (lane 4). This suggests that TSE2 binds the heterodimer SCX/E47. The presence of an Xpress tag at the N-terminal end of SCX enabled us to perform experiments in the presence of anti-Xpress antibodies. The addition of an anti-Xpress antibody (Invitrogen) to the reaction mixture largely decreased the formation of the retarded complex (lane 6 in Fig. 1A ). In addition, as shown in Fig. 1B , the shifted complex induced by incubation of TSE2 with nuclear extracts from COS-7 cells transfected with pcDNA-SCX plus pCI-E47 was competed by addition of unlabeled TSE2, but also of unlabeled AgE. AgE is a sequence of the aggrecan promoter that has been shown to bind SCX. Taken together, these results indicate that TSE2 can bind SCX when it is heterodimerized with E47.
The binding of SCX/E47 heterodimers to TSE2 enhances the activity of the COL1a1 promoter
The ability of SCX/E47 heterodimers to bind TSE2 and enhance the activity of the COL1a1 minimal promoter was tested in transient transfection experiments. Eukaryotic expression vectors encoding SCX (pcDNA-SCX) and E47 (pCI-E47) were cotransfected with a reporter plasmid containing four copies of TSE2 cloned upstream of 220 bp of the mouse COL1a1 proximal promoter and of the lacZ reporter gene (p4TSE2mp), in NIH/3T3 cells. This 220-bp segment of the COL1a1 proximal promoter has been shown to have characteristics of a minimal promoter (6) . The NIH/3T3 cells are embryonic fibroblastic cells which synthesize type I collagen but do not express SCX (data not shown). Cotransfection of pcDNA-SCX plus pCI-E47 induced a strong and dose-dependent increase in the levels of expression of p4TSE2mp ( Fig. 2A) . When 200 ng of each of these two expression vectors were cotransfected, the levels of expression of p4TSE2mp were increased about 15 fold. Transfection of pcDNA-SCX had significant but weaker enhancing effects ( Fig. 2A) . Transfection of E47 had almost no transactivating effects ( Fig. 2A) .
Transfection experiments were then repeated using pJ320 instead of p4TSE2mp. pJ320 contains a 3.2-kb segment of the mouse COL1a1 proximal promoter cloned upstream of the lacZ reporter gene, and it is expressed at high levels in tendons and ligaments of transgenic mice (4, 8) . Overexpression of SCX plus E47 increased the transcriptional activity of pJ320 up to 10 fold, and this transactivating effect was dose-dependent (Fig. 2B) . By contrast, transfection of pCI-E47 alone had less transactivating effects on pJ320, and transfection of pcDNA-SCX alone had no transactivating effects (Fig. 2B) . Overexpression of SCX plus E12 also had almost no transactivating effects on the activity of pJ320 (data not shown). Interestingly, in C2 myoblasts, a mesenchymal cell line that does not express type I collagen, cotransfection of pcDNA-SCX plus pCI-E47 very slightly enhanced the expression of pJ320 (Fig. 2C ). This suggests that SCX/E47 heterodimers need to cooperate with other nuclear proteins that are present in NIH/3T3 cells but not in C2 cells.
Since the 3.2-kb segment of the COL1a1 proximal promoter contains nine consensus Eboxes (CANNTG), transfection experiments were repeated using a reporter construct in which the E-box of TSE2 had been mutated (pJ320-MTSE2). The mutation of this E-box decreased by about 30% the transcriptional activation induced by transfection of 200 ng of pcDNA-SCX plus 200 ng of pCI-E47 (Fig. 2D) .
Taken together, these results indicate that SCX can transactivate reporter constructs containing TSE2, and these transactivating effects appear to be mostly mediated by the binding of SCX/E47 heterodimers to the E-box of TSE2.
SCX/E47 heterodimers need to cooperate with other nuclear factors, in order to transactivate the COL1a1 proximal promoter.
Transgenic experiments have shown that TSE2 needs to cooperate with another tendonspecific cis-acting element, named TSE1, in order to drive reporter gene expression in tendon fibroblasts (8) . This led us to test the effects of overexpression of SCX and E47 on pJ320, in stable transfection experiments. pcDNA-SCX and pCI-E47 expression vectors were cotransfected in pools of NIH/3T3 cells that had previously been stably transfected with pJ320. Unlike what had been observed in transient transfection experiments, overexpression of SCX plus E47 did not increase the activity of the lacZ reporter gene (Fig 2E) . Thus, as shown in transgenic experiments, SCX needs to cooperate with other DNA-binding elements in order to exert its transactivating effects on the COL1a1 promoter, when it is stably integrated into the genome.
NFATc transcription factors are expressed in tendon fibroblasts
Bioinformatic analysis of the 3' half of TSE1 revealed the presence of few potential binding sites for transcription factors, but a motif at -2,776 bp which corresponds to the core sequence of a potential NFATc binding site (GGAAA) (30); this motif being conserved between species (data not shown). Interestingly, NFATc DNA-binding proteins have been shown to play a role in the development of heart valves, which share common features with tendons such as the expression of tenascin (31) (32) (33) . They have also recently been shown to cooperate with Osterix to enhance the expression of COL1a1 in osteoblasts (34) . We thus decided to study the expression of the NFATc genes in tendon fibroblasts, and the ability of the corresponding proteins to bind TSE1 and transactivate the COL1a1 promoter.
We first performed RT-PCR experiments to examine the presence of mRNAs encoding the different NFATc proteins in TT-D6 cells. This cell line has been derived from Achilles tendons of transgenic mice harboring a temperature-sensitive mutant of SV40 large T antigen, and it has characteristics of tendon fibroblasts (23) . Spleen mRNA was used as positive control, since NFATc1-3 mRNAs, and to a lesser extent NFATc4 mRNA, are present in this organ. As shown in Fig. 3A , mRNAs corresponding to NFATc1, NFATc3 and NFATc4, but not NFATc2, were detected in TT-D6 cells. Western blot experiments performed using total cell lysates from TT-D6 cells showed that the NFATc1, NFATc3 and NFATc4 proteins were expressed in these cells, but at low levels (data not shown). The activity of the NFATc proteins is mainly regulated by their subcellular localization, and only the hypophosphorylated NFATc proteins present in the nucleus can bind DNA and activate transcription. To determine if the NFATc proteins present in TT-D6 cells were present in the nucleus, we performed Western blot experiments using nuclear extracts from TT-D6 cells. Cellular extracts from COS-7 cells transfected with expression vectors encoding NFATc1, NFATc3 or NFATc4 were used as positive controls. NFATc4 was detected in nuclear extracts from TT-D6 cells, while NFATc1 and NFATc3 proteins could not be detected even after prolonged exposure (Fig. 3B and data not shown). These data suggest that only the NFATc4 protein is activated and translocated into the nucleus, in TT-D6 fibroblasts. Interestingly, C2 cells did not express NFATc4 mRNA (data not shown).
In order to establish the in vivo relevance of the presence of NFATc proteins in TT-D6 cells, we performed in situ hybridization experiments to analyze NFATc expression in limb tendons of mouse embryos. The tendons were visualized using a probe for the tendon marker SCX (Fig. 3C, F) . As shown by the partial co-localization of SCX and NFATc4, NFATc4 transcripts were clearly expressed in E15.5 and E18.5 limb tendons (Fig. 3C, E and data not shown). At these stages, type I collagen genes were expressed in developing tendons (data not shown). Interestingly, NFATc4 transcripts were also observed around cartilage elements (Fig. 2C, D) . In these structures, NFATc4 was not colocalized with SCX. No NFATc1 and NFATc3 expression was detected in developing limb tendons, while both genes were clearly expressed in adult spleen (data not shown).
These results show that mouse tendon fibroblasts and a tendon fibroblastic cell line express the NFATc4 gene.
NFATc proteins bind TSE1 and transactivate the COL1a1 proximal promoter
To test the ability of NFATc proteins present in TT-D6 cells to bind TSE1, we performed gel shift assays. Incubation of nuclear extracts from TT-D6 cells with an end-labeled TSE1 probe induced the appearance of a shifted complex (Fig. 4, lane 1) . This complex was competed by an excess of unlabeled TSE1 probe (Fig. 4, lane 2) but not by a mutated probe deleted of the GGAAA motif (Fig. 4,  lane 3) . Similarly, it was competed by a doublestranded oligonucleotide corresponding to a welldescribed NFATc binding site in the mouse IL-4 promoter, but not by an oligonucleotide in which this binding site had been mutated (Fig. 4, lanes 4-9) . Taken together, these results indicate that TSE1 binds NFATc proteins that are present in tendon fibroblasts.
To determine whether the binding of NFATc to TSE1 can transactivate the COL1a1 proximal promoter, NIH/3T3 fibroblastic cells were cotransfected with an expression vector encoding NFATc1 (pREP-NFATc1), NFATc3 (pREPNFATc3) or NFATc4 (pREP-NFATc4) and with a reporter construct harboring four copies of TSE1 cloned upstream of the mouse COL1a1 minimal promoter and of the lacZ gene (p4TSE1mp). Overexpression of NFATc1, NFATc3 and NFATc4 significantly increased the activity of p4TSE1mp (Fig. 5) .
Taken together, these data demonstrate that NFATc proteins can bind TSE1 and transactivate the COL1a1 proximal promoter.
NFATc proteins regulate the expression of type I collagen genes in tendon fibroblasts
To further explore the ability of NFATc proteins to regulate the transcription of COL1a1, we used the calcineurin inhibitor CsA. By blocking the phosphatase activity of calcineurin, CsA inhibits the dephosphorylation of NFATc and thus its nuclear translocation (20) . The expression of COL1a1 mRNA in TT-D6 cells treated with various amounts of CsA was analyzed by real-time RT-PCR. As shown in Fig. 6A , treatment with CsA induced a dramatic and dose-dependent decrease in the levels of COL1a1 mRNA; this reduction reaching about 90% when TT-D6 cells were incubated with 20 µg/mL (i.e. 16.6 nmol/mL) of CsA (Fig. 6A) . Since there is a coordinated regulation of COL1a1 and COL1a2, we analyzed the ability of NFATc proteins to regulate the expression of COL1a2. Treatment of TT-D6 cells with CsA induced a strong and dosedependent inhibition of the expression of the pro-α2(I) collagen gene (data not shown).
To confirm that the inhibition of the expression of COL1a1 induced by CsA was due to cytoplasmic retention of NFATc proteins and not to effects of CsA that are independent of calcineurin inhibition, TT-D6 fibroblasts were treated with INCA-6. This small organic molecule specifically inhibits the interactions between NFATc and calcineurin (27) . As with CsA, we observed a strong and dose-dependent decrease in the levels of COL1a1 mRNA (Fig.  6B) . Treatment of TT-D6 cells with INCA-6 also strongly inhibited the expression of the pro-α2(I) collagen gene (data not shown).
Thus, NFATc transcription factors appear to be potent regulators of the expression of COL1a1 and COL1a2 in tendon fibroblastic cells.
NFATc proteins regulate type I collagen genes expression in cells different from tendon fibroblasts.
Since NFATc proteins are expressed in a large number of cell types, we decided to analyze the expression of the NFATc genes in a fibroblastic cells line different from TT-D6 cells, and the effects of treatment with CsA and INCA-6 on the expression of COL1a1 mRNA in this cell line. We chose to use NIH/3T3 cells, which is a well-known fibroblastic cell line (35) . RT-PCR experiments showed the presence of NFATc1, NFATc3 and NFATc4 mRNAs in NIH/3T3 fibroblasts (Fig. 7A) . However, Western blot analyses only demonstrated the presence of NFATc3 and NFATc4 proteins in total cell lysates and nuclear extracts from NIH/3T3 cells (data not shown and Fig. 7B ).
Real-time RT-PCR experiments showed that treatment of NIH/3T3 cells with CsA or INCA-6 induced an important and dose-dependent inhibition of the expression of the COL1a1 and COL1a2 mRNA (Fig. 7C, D, and data not shown) .
Thus, NFATc proteins are expressed in fibroblasts different from tendon fibroblasts, and also appear to regulate the expression of type I collagen genes in these cells.
DISCUSSION
Molecular mechanisms governing the tissuespecific expression of type I collagen genes are still elusive. In particular, transcription factors that direct their expression in fibroblasts have not been identified yet. By generating transgenic mice harboring various segments of the COL1a1 proximal promoter cloned upstream of the lacZ reporter gene, we have previously shown that two short cis-acting elements, named TSE1 and TSE2, are necessary for activation of this promoter specifically in tendon fibroblasts (8) . Here, we have used gel shift assays to show that SCX can bind the E-box of TSE2, preferentially as an heterodimer with E47. This observation is consistent with our previous results showing that this E-box binds a DNA-binding protein expressed selectively in tendon fibroblasts (8) . It is also consistent with previous experiments showing that SCX can heterodimerize with E47 to bind an E-box sequence of the muscle creatine kinase promoter, which is a known target of a variety of bHLH proteins (15) . However, other studies have shown that SCX can also bind E-boxes as an homodimer or as a SCX/E12 heterodimer (12, 25) . As for other bHLH proteins, the sequence of the regions flanking the E-box are likely to play an important role in modulating the binding affinity of these dimers (36) . Several arguments indicate that the binding of SCX to TSE2 transactivates the COL1a1 promoter. First, overexpression of SCX and E47 strongly enhanced the activity of a reporter construct containing four copies of TSE2 cloned upstream of the COL1a1 minimal promoter (p4TSE1mp), in transient transfection experiments. Second, overexpression of these two DNA-binding proteins strongly activated a reporter construct harboring a 3.2-kb segment of the COL1a1 proximal promoter (pJ320). Third, when the E-box of TSE2 was deleted in pJ320, it significantly decreased the transactivating effects of SCX/E47 heterodimers.
The fact that a deletion of this E-box did not completely abolish the transactivating effects of SCX is probably due to the existence of eight Eboxes downstream of TSE2 in the COL1a1 proximal promoter. Interestingly, overexpression of SCX alone or of SCX plus E12 had very limited transactivating effects on the COL1a1 proximal promoter, which is in good agreement with the results of the gel shift experiments (data not shown). Although overexpression of SCX has recently been shown to enhance the expression of the tenomodulin gene in tendon fibroblasts (17) , so far no gene had been shown to be directly regulated by SCX in tendon cells. Thus, COL1a1 is the first direct target of SCX to be identified in tendon fibroblasts. It should be stressed that, in transient transfection experiments performed using C2 myoblastic cells, overexpression of SCX plus E47 did not transactivate pJ320, which suggests that SCX interacts with nuclear proteins that are present in fibroblastic cells but not in myoblastic cells. Consistent with this result, overexpression of SCX enhanced the expression of the tenomodulin gene in tendon fibroblasts but not in nontendinous cells such as myoblasts or chondrocytes (17) .
Since the discovery of the first NFATc protein, it has been clear that members of this family of transcription factors have crucial roles in the development and function of the immune system (37). However, analyses of knock-out mice have shown that they are also involved in other developmental processes, such as cardiovascular and skeletal muscle development, neural development, chondrogenesis, osteoclast differentiation or osteoblastic bone formation (21, 34) . Thus, because TSE1 contains a consensus binding site for NFATc proteins (30), we focused on a potential role for these proteins in activating COL1a1 in tendon fibroblasts. Analysis of the expression of the NFATc genes showed that NFATc4 is expressed and activated in tendon fibroblasts. RT-PCR experiments performed using mRNA from TT-D6 cells disclosed the presence of NFATc4 mRNA, and Western blot analyses showed that NFATc4 was present in nuclear extracts from these cells. In addition, in situ hybridization experiments showed that NFATc4 mRNA was present in tendons of developing mouse limbs, where it was colocalized with SCX mRNA. By contrast, we could not detect the presence of NFATc1 or NFATc3 proteins in nuclear extracts from TT-D6 cells and in situ hybridization experiments also did not detect the corresponding mRNAs in tendons of developing mouse limbs. However, RT-PCR experiments disclosed the presence of NFATc1 and NFATc3 mRNA in TT-D6 cells and Western blot analyses of total cell lysates showed low amounts of the NFATc1 and NFATc3 proteins. Thus, it seems that NFATc1 and NFATc3 are present in the cytoplasm of these cells, but are not activated and not transported into the nucleus. Selective activation of NFATc proteins has already been described (22) . Because tendon fibroblasts appear to contain NFATc4, we studied the ability of NFATc proteins to bind TSE1 and transactivate the COL1a1 gene. Three arguments suggest that NFATc proteins regulate the activity of COL1a1 in tendon fibroblasts through their binding to TSE1. First, gel shift assays showed that TSE1 can bind NFATc proteins that are present in nuclear extracts from TT-D6 tendon fibroblastic cells. Incubation of a TSE1 probe with nuclear extracts from TT-D6 cells induced the appearance of a single retarded complex that was competed by a double-stranded oligonucleotide corresponding to a consensus NFATc binding site, but not by a mutated one. This complex was also not competed by a TSE1 double-stranded oligonucleotide in which the consensus binding site for NFATc had been deleted. Second, in transient transfection experiments, overexpression of NFATc had transactivating effects on a reporter construct containing four copies of TSE1 cloned upstream of the COL1a1 minimal promoter. Third, inhibition of the nuclear translocation of NFATc proteins by two unrelated pharmacologic molecules, CsA and INCA-6, induced a dramatic and dose-dependent inhibition of the expression of COL1a1 in TT-D6 tendon fibroblastic cells. CsA is a pharmacologic agent that has been widely used to inhibit the nuclear translocation of NFATc transcription factors, and thus their transactivating effects. However, it inhibits the enzymatic activity of calcineurin toward all its physiological substrates and can thus block all signaling downstream of calcineurin (38) . By contrast, INCA-6 is a newly-developed small organic molecule that specifically blocks targeting of calcineurin to NFATc by inhibiting the interaction between these two proteins, and that does not prevent the dephosphorylation of other substrates (27) . Interestingly, Koga et al have recently demonstrated that NFATc proteins regulate the activity of the COL1a1 gene in osteoblasts (34) . In particular, they have shown (1) that overexpression of NFAT proteins slightly but significantly enhances the activity of the COL1a1 proximal promoter in osteoblastic cells, and (2) that treatment of osteoblasts with FK506, a pharmacologic agent that is closely related to CsA and also inhibits the dephosphorylation of NFATc proteins, strongly reduces the mRNA expression of COL1a1 (34) . Thus, NFATc could have similar transactivating effects on COL1a1 in osteoblasts and tendon fibroblasts. In addition, Koga et al have shown that NFATc1 interacts with Osterix, a transcription factor that plays a key role in bone development and osteoblast differentiation (39) , to activate the COL1a1 promoter (34) . Hence, NFATc proteins appear to cooperate with Osterix to activate the COL1a1 gene in osteoblasts and with SCX to activate this gene in tendon fibroblasts. Analyses of knockout mice have also shown that NFATc1 is indispensable for early development of heart valves (31, 32, 40) , but its role in the differentiation of heart valve fibroblasts remains unknown. An attractive hypothesis would be that NFATc1 also cooperates with another transcription factor, such as Sox9 (41), to induce the differentiation of heart valve fibroblasts and expression of COL1a1. Since our data suggest that NFATc proteins are also involved in activation of the COL1a1 gene in NIH/3T3 fibroblastic cells, they could even have a more general role in activation of the collagen genes in fibroblastic cells.
In conclusion, our data show that NFATc proteins and SCX activate the COL1a1 gene in tendon fibroblasts through their binding to TSE1 and TSE2, respectively. These two transcription factors are probably part of a larger transcriptional network that induces the differentiation of mesenchymal cells into tendon fibroblasts. Competition experiments were performed using unlabeled doublestranded oligonucleotides corresponding to TSE2 or to a sequence of the aggrecan promoter that contains two E-boxes and is known to bind SCX (AgE). The labeled TSE2 probe was incubated with nuclear extracts from COS-7 cells transfected with pcDNA-SCX plus pCI-E47 in the absence of competitor (-) or in the presence of a 200-fold molar excess of unlabeled TSE2 (TSE2) or AgE (AgE). The retarded complex was competed by TSE2 and AgE oligonucleotides, as shown on a gel exposed for a prolonged period of time. Gel shift experiments were performed using an end-labeled double-stranded oligonucleotide corresponding to TSE1 and nuclear extracts from TT-D6 tendon fibroblasts. A single retarded complex was observed when nuclear extracts were incubated with the TSE1 probe (lane 1, arrow), and this complex was competed by a 20-fold molar excess of unlabeled TSE1 (lane 2), but not by a probe in which the GGAAA sequence had been deleted (ΔTSE1, lane 3). This complex was also competed by an unlabeled double-stranded oligonucleotide corresponding to a consensus NFATc binding site in the promoter of the IL-4 gene (IL-4wt, lanes 4-6). By contrast, it was not competed by a double-stranded oligonucleotide corresponding to IL-4wt but harboring a mutation in the NFATc binding site (IL-4mut, lanes 7-9). 
